214 related articles for article (PubMed ID: 35227966)
21. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
Ou SI; Solomon BJ; Shaw AT; Gadgeel SM; Besse B; Soo RA; Abbattista A; Toffalorio F; Wiltshire R; Bearz A
J Thorac Oncol; 2022 Apr; 17(4):568-577. PubMed ID: 35026476
[TBL] [Abstract][Full Text] [Related]
22. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
[TBL] [Abstract][Full Text] [Related]
23. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
24. Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Barata F; Aguiar C; Marques TR; Marques JB; Hespanhol V
Drug Saf; 2021 Aug; 44(8):825-834. PubMed ID: 34080177
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
26. Lorlatinib for the treatment of patients with non-small cell lung cancer.
Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
[TBL] [Abstract][Full Text] [Related]
27. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
28. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
[TBL] [Abstract][Full Text] [Related]
29. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Nilsson FOL; Asanin ST; Masters ET; Iadeluca L; Almond C; Cooper M; Smith S
Pharmacoeconomics; 2021 Aug; 39(8):941-952. PubMed ID: 34080140
[TBL] [Abstract][Full Text] [Related]
30. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
[TBL] [Abstract][Full Text] [Related]
32. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.
Liao Y; Remsing Rix LL; Li X; Fang B; Izumi V; Welsh EA; Monastyrskyi A; Haura EB; Koomen JM; Doebele RC; Rix U
Cell Chem Biol; 2024 Feb; 31(2):284-297.e10. PubMed ID: 37848034
[TBL] [Abstract][Full Text] [Related]
33. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
34. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT
JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological and clinical properties of lorlatinib in the treatment of
El Darsa H; Abdel-Rahman O; Sangha R
Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
Chen J; O'Gorman MT; James LP; Klamerus KJ; Mugundu G; Pithavala YK
Clin Pharmacokinet; 2021 Oct; 60(10):1313-1324. PubMed ID: 33937954
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Chen J; Houk B; Pithavala YK; Ruiz-Garcia A
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):148-160. PubMed ID: 33449423
[TBL] [Abstract][Full Text] [Related]
39. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
[TBL] [Abstract][Full Text] [Related]
40. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Felip E; Shaw AT; Bearz A; Camidge DR; Solomon BJ; Bauman JR; Bauer TM; Peters S; Toffalorio F; Abbattista A; Thurm H; Peltz G; Wiltshire R; Besse B
Ann Oncol; 2021 May; 32(5):620-630. PubMed ID: 33639216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]